Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritidesArticle Published on 2022-10-012022-11-15 Journal: Joint bone spine [Category] 진단, [키워드] Abstract anti-cytokine therapy anti-SARS-CoV-2 arthritide bDMARDs. COVID-19 Inflammatory Patient serology T-cell targeted therapy vaccination vaccine response [DOI] 10.1016/j.jbspin.2022.105391 PMC 바로가기
Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysisArticle Published on 2022-10-012022-11-15 Journal: Transplantation [Category] 진단, [키워드] 95% CI 95% confidence interval age Allogeneic calcineurin Cell combating Comorbidity coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccines dose Effects Factor General population healthy control higher risk humoral Immunocompromised Immunosuppressant immunosuppressive inclusion criteria increased risk inhibitor inhibitors mammalian medication Meta-analysis much lower Organ transplant outcome pandemic performed pooled rate Population Rapamycin receiving recipient recipients regimen response review risk factor second dose Seroconversion seroconversion failure Steroids systematic review the vaccine Transplant Vaccine vaccine response [DOI] 10.1097/TP.0000000000004256 PMC 바로가기
Predicting a Positive Antibody Response After 2 SARS-CoV-2 mRNA Vaccines in Transplant Recipients: A Machine Learning Approach With External ValidationArticle Published on 2022-10-012022-11-15 Journal: Transplantation [Category] COVID19(2023년), SARS, 진단, [키워드] Antibody Response Antibody testing association BNT162b2 calculator characteristic clinical factor clinical factors Cohort contributing to dose External external validation facilitate Follow-up help Houston identify immunosuppressants less machine learning moderate mRNA mRNA vaccines mRNA-1273 mycophenolate mofetil negative antibody response Older age organ Other Patient Precision predictor protective immunity recipient recommendations response risk factor risk stratification SARS-CoV-2 Sex solid organ Transplant understanding Vaccination strategy Vaccine vaccine dose vaccine response validation was performed [DOI] 10.1097/TP.0000000000004259 PMC 바로가기
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccinationArticle Published on 2022-10-012022-11-16 Journal: RMD Open [Category] COVID19(2023년), SARS, 변종, [키워드] administration Arthritis booster booster vaccination control group COVID-19 COVID-19 vaccination demonstrated Epidemiology impairment medication methotrexate mRNA MTX neutralisation neutralising Observational cohort study occur omicron Patient Prevent pseudovirus neutralisation assay reached receiving SARS-CoV-2 serum significantly higher significantly lower therapy Treatment vaccination vaccine response variant variants were assessed while wild-type [DOI] 10.1136/rmdopen-2022-002639 PMC 바로가기
Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipientsArticle Published on 2022-09-152022-11-15 Journal: Trials [Category] SARS, 진단, [키워드] 1:1 binding domain Booster vaccine cell-mediated response clinical Controlled trial COVID COVID-19 COVID-19 vaccination COVID-19 vaccine death develop disease severity dose Effectiveness Efficacy ENhance hospitalisation humoral hypothesise IgG immune cell population immunological Immunosuppression IMPROVE include increased risk Intervention kidney transplant recipient kidney transplant recipients Kidney transplantation live SARS-CoV-2 Modification mTOR inhibitor multicentre neutralisation New outcome participant Prednisolone Primary outcome proportion Protective protective immunity public health randomised randomised controlled trial Rapamycin recipient reduce reduced regimen registry responses SARS-CoV-2 SARS-CoV-2 vaccine secondary serological Sirolimus Standard of care Study protocol Tolerability Trial vaccination Vaccine vaccine response virus [DOI] 10.1186/s13063-022-06634-w PMC 바로가기
Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessmentArticle Published on 2022-09-152022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, 치료제, [키워드] anti-N antibody anti-S anti-S antibody Anti-SARS-CoV-2 S antiviral therapy can be used Cancer patients comparable correlated correlation COVID-19 Critical Elecsys® Anti-SARS-CoV-2 S evaluate expected Follow-up group Immune status immunoassay immunosuppressed patients in both groups linear Mild moderate Neutralization antibody Neutralization assay Neutralizing activity neutralizing antibody onset of symptom Patient patients patients with COVID-19 performance positive predict produced Proteins Roche SARS-CoV-2 neutralizing antibody serum serum sample significantly higher vaccine response Virus neutralization [DOI] 10.1371/journal.pone.0274181 PMC 바로가기
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiencyArticle Published on 2022-09-142022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] activity Adverse reaction analyzed Anti-SARS-CoV-2 S antibody Antibody Response Autoimmune Autoimmune diseases B-lymphocytes Cell Cohort cohort of patient comparable Course COVID-19 COVID-19 vaccination CVID deficiency detect Disease activity dysfunction effective Efficacy and safety Elecsy flow cytometry healthy control humoral humoral immune response Hypogammaglobulinemia IFN-gamma immune system Immunity immunization immunoassay immunodeficiency immunoglobulin replacement therapy in healthy individuals increased risk individual Interferon-gamma lymphocyte neutralization Patient Phenotyping pneumococcal provide reactogenicity receptor Safe SARS-COV-2 infection selective Seven subjects Support syndrome T cell response T-lymphocites the disease triggering underlying disease vaccination vaccine response Vero E6 Virus neutralization was performed well X-linked agammaglobulinemia XLA [DOI] 10.3389/fimmu.2022.974987 PMC 바로가기
Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]Article Published on 2022-09-082022-11-15 Journal: Journal of Crohn's & colitis [Category] SARS, 진단, [키워드] Affect Against antagonists anti-SP IgG Anti-spike anti-TNF anti-tumour necrosis factor antagonists. Antibody Response booster vaccination bowel Cohort Complete COVID-19 COVID-19 vaccination determine Diagnosis diminished healthy control highlight IBD Immunoglobulin Impaired Inflammatory bowel disease inhibitor investigated medication mRNA vaccine Necrosis Patient Protein Quantitative receiving recruited response response to vaccination Result SARS-CoV-2 vaccination seroconvert seroconverted serological response significantly lower therapy TNF TNF antagonist Treatment vaccination vaccination against COVID-19 Vaccine vaccine response were assessed [DOI] 10.1093/ecco-jcc/jjac029 PMC 바로가기
Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue: December 2020-August 2021Article Published on 2022-09-012022-11-15 Journal: Journal of occupational and environmental medicine [Category] 진단, [키워드] anti-spike IgG level antiviral antibody average change COVID-19 COVID-19 case COVID-19 vaccination declined decrease demographics enzyme-linked immunosorbent assay evaluate Follow-up Humoral response IgG individual Infection information neutralizing capacity North over participant participated Potential provided questionnaire Risk factors serum significantly spike time vaccination Vaccine vaccine availability vaccine response were used [DOI] 10.1097/JOM.0000000000002617 PMC 바로가기
Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residentsArticle Published on 2022-09-012022-11-15 Journal: Immunity, Inflammation and Disease [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome addressed Alpha variant antibody attack rate B.1.1.7 B.1.351 Beta Breakthrough infection Care caused cell-mediated immune response Cell-mediated immunity concentrations coronavirus COVID-19 COVID-19 outbreak COVID-19 vaccination elderly HCWs healthcare worker high risk IgG Immunity Immunoglobulin Impaired investigated Long-term care Long-term care facility marker NAb titer Neutralizing antibodies neutralizing antibody outbreak protocols SARS-CoV-2 variant second dose severe coronavirus disease spike glycoprotein susceptible vaccination vaccine doses vaccine response Vaccine-induced immunity variant variants [DOI] 10.1002/iid3.679 PMC 바로가기